← Oncology Approval Tracker

FDA DECISION ·

Vanflyta + chemotherapy

quizartinib + induction and consolidation chemotherapy · Daiichi Sankyo

FDA approvalNew therapyAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with newly diagnosed FLT3-ITD-positive AML confirmed by an FDA-approved test. Use with standard induction and consolidation, followed by quizartinib maintenance.

LAMPGEN ANALYSIS

Why it matters

The approval spanned multiple treatment phases for a specific FLT3 alteration.

What research teams should watch

Return FLT3-ITD testing promptly and plan phase-specific dosing and QT monitoring.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Newly diagnosed, molecularly selected AML

PRIMARY RECORDS

Sources